T-MAXIMUM Pharmaceutical (T-MAXIMUM) is a clinical-stage biotech company based in Suzhou, China focusing on the development of allogeneic universal CAR-T cell therapies for solid tumors. It’s core technology platform utilizes a fully proprietary gene-edited immuno-cellular therapy approach. This approach limits the risks of graft-versus-host disease and rejection, allowing allogeneic CAR-T cells persist within the patient's body for an extended period, thereby achieving optimal therapeutic effects with Best-in-Class potential. T-MAXIMUM is currently focusing on advanced-stage malignancies, with its lead pipeline product for recurrent high-grade glioma (rHGG) demonstrating breakthrough efficacy and manageable safety in initial clinical studies and obtained Orphan Drug Designation (ODD) from the US FDA.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.t-maximum.com/
T-Maximum Pharmaceutical Questions
T-Maximum Pharmaceutical's website is http://www.t-maximum.com/
T-Maximum Pharmaceutical's LinkedIn profile is https://www.linkedin.com/company/t-maximum-pharmaceutical
T-Maximum Pharmaceutical's industry is
Biotechnology Research
T-Maximum Pharmaceutical's top competitors are
Accellapy,
Evive Biotech,
Interius Biotherapeutics,
Day One Biopharmaceuticals,
Spring House Innovation Park,
Indapta Therapeutics,
Genentech,
Zai Lab,
Third Arc Bio,
Seed Therapeutics.
T-Maximum Pharmaceutical's categories are Biotechnology Research
T-Maximum Pharmaceutical's founding year is 2017
